Official ESCRS | European Society of Cataract & Refractive Surgeons

 

Clinical outcomes of a new extended-vision intraocular lens implanted by Spanish surgeons

Search Title by author or title

Session Details

Session Title: Extended-Depth-Of-Focus IOLs II

Session Date/Time: Monday 16/09/2019 | 14:00-16:00

Paper Time: 14:18

Venue: Free Paper Forum: Podium 1

First Author: : M.Guarro SPAIN

Co Author(s): :    J. Pedrell   C. Peris   J. Álvarez de Toledo Elizalde   F. Poyales                    

Abstract Details

Purpose:

To evaluate the visual outcomes of subjects implanted with a non-diffractive extended vision intraocular lens (DFT015) at six sites in Spain

Setting:

Multicenter

Methods:

Six surgeons in Spain bilaterally implanted 51 subjects with DFT015 and 38 with the monofocal control (SN60WF) as part of a prospective, randomized, subject and assessor masked trial. At 6 months after the second eye implant, the binocular defocus curve, binocular distance corrected visual acuities (VAs) at distance (BCDVA, 4 m), intermediate (DCIVA, 66 cm) and near (DCNVA, 40 cm), and visual disturbances of halos, glare and starbursts (QoV, McAlinden) were assessed.

Results:

The DFT015 binocular defocus curve demonstrated >0.5 D of extension over SN60WF at 0.2 logMAR. Binocular BCDVA was better than 0.0 logMAR for both groups with only a 2 letter reduction in binocular BCDVA with DFT015 compared to SN60WF. At intermediate and near, the improvement in binocular distance corrected VA for DFT015 over SN60WF was ≥ 0.1 logMAR. In the DFT015 group, 69% or more subjects were not at all bothered by halos, starbursts and glare; while 57% or more subjects were not at all bothered by these visual disturbances with SN60WF.

Conclusions:

Compared with SN60WF, bilateral implantation of this non-diffractive extended vision IOL provided subjects with an extended range of vision from distance to near, without increasing the incidence of visual disturbances.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a competing company

Back to previous